A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the Dialysis Clinical Outcomes Revisited (DCOR) Randomized Trial Using Claims Data

American Journal of Kidney Diseases

Volumn 51, Issue 3, 2008, Pages 445-454

  St Peter, Wendy L ^a,b   Liu, Jiannong ^a   Weinhandl, Eric ^a   Fan, Qiao ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Calcium based phosphate binders; end stage renal disease; hospitalization; morbidity; mortality; sevelamer

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; PHOSPHATE BINDING AGENT; SEVELAMER; TUMS; VITAMIN D;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ACETATES; AGED; CALCIUM COMPOUNDS; CHELATING AGENTS; FEMALE; HEMODIALYSIS SOLUTIONS; HOSPITALIZATION; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYAMINES; RENAL DIALYSIS;

EID: 39449117385     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.12.002     Document Type: Article

References (16)

1. Block G.A., Hulbert-Shearon T.E., Levin N.W., and Port F.K. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31 (1998) 607-617
2. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., and Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 (2004) 2208-2218
3. Slinin Y., Foley R.N., and Collins A.J. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol 16 (2005) 1788-1793
4. Young E.W., Albert J.M., Satayathum S., et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 (2005) 1179-1187
5. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 (2006) 771-780
6. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 42 (2000) 1478-1483
7. London G.M., Guérin A.P., Marchais S.J., Métivier F., Pannier B., and Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 (2003) 1731-1740
8. Blacher J., Guerin A.P., Pannier B., Marchais S.J., and London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 (2001) 938-942
9. Chertow G.M., Burke S.K., Raggi P., and Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 (2002) 245-252
10. Block G.A., Spiegel D.M., Ehrlich J., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 (2005) 1815-1824
11. Suki W.A., Zabaneh R., Cangiano J.L., et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72 (2007) 1130-1137
12. Therneau T.M., and Grambsch P.M. Modeling Survival Data: Extending the Cox Model (2000), Springer-Verlag, New York, NY 169-229
13. Block G.A., Raggi P., Bellasi A., Kooienga L., and Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71 (2007) 438-441
14. Thompson J.R. Invited commentary: Re: "Multiple comparisons and related issues in the interpretation of epidemiologic data.". Am J Epidemiol 147 (1998) 801-806
15. Cook D.I., Gebski V.J., and Keech A.C. Subgroup analysis in clinical trials. Med J Aust 180 (2004) 289-291
16. Bland J.M., and Altman D.G. Multiple significance tests: The Bonferroni method. BMJ 310 (1995) 170